Athira Pharma

Last updated
Athira Pharma Inc.
Nasdaq:  ATHA
IndustryBiotechnology, Pharmaceuticals
Founded2011
Headquarters
Seattle
,
United States
ProductsATH-1017
Website www.athira.com

Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. [1]

Contents

The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors. [2] [3] [4]

Leen Kawas served as the company's first President and CEO, [5] but resigned in October 2021, [6] after an independent special committee found she "altered images in scientific papers she authored." [7] On October 21, 2021, Mark Litton, Ph.D., M.B.A. became Chief Executive Officer. [7]

History

The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date. [8] Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11, 2019. [9] [10]

Core technology

The company's lead asset, ATH-1017, is in human trials of Alzheimer's disease as of 2021. [11] ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function. [12] It aims to regenerate lost connections in the brain, protect brain cells from further damage, and prevent additional neuronal deterioration. [13] ATH-1017 is currently being tested in two clinical studies: ACT-AD and LIFT-AD. [14]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Memantine</span> Medication used to treat Alzheimers disease

Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.

<span class="mw-page-title-main">Eisai (company)</span> Japanese pharmaceutical company

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">GTS-21</span> Chemical compound

GTS-21 is a drug that has been shown to enhance memory and cognitive function. It has been studied for its potential therapeutic uses, particularly in the treatment of neurodegenerative diseases and psychiatric disorders.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Gladstone Institutes</span>

Gladstone Institutes is an independent, non-profit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators, 2012 Nobel Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration.

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

<span class="mw-page-title-main">Rudolph E. Tanzi</span> American geneticist

Rudolph Emile 'Rudy' Tanzi a professor of Neurology at Harvard University, vice-chair of neurology, director of the Genetics and Aging Research Unit, and co-director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital (MGH).

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease (AD). It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion.

The Alzheimer's Drug Discovery Foundation (ADDF) is a nonprofit organization founded in 1998 by co-chairmen Leonard A. Lauder and Ronald S. Lauder of the Estée Lauder Companies cosmetics family and led by Howard Fillit, a geriatrician and neuroscientist. The ADDF provides funding to scientists who are conducting promising, innovative Alzheimer's disease drug research worldwide. The ADDF funds early-stage research and early-phase clinical trials that might otherwise go unfunded. By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related dementias and cognitive aging. The ADDF has invested nearly $65 million to fund some 450 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.

<span class="mw-page-title-main">Dihexa</span> Chemical compound

Dihexa, also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.

Steven M. Paul is an American neuroscientist and pharmaceutical executive. As of 2021, Paul serves as the CEO, president and chairman of Karuna Therapeutics.

<span class="mw-page-title-main">Giovanna Mallucci</span> British neuroscientist

Giovanna Rachele Mallucci is van Geest Professor of Clinical Neurosciences at the University of Cambridge in England and associate director of the UK Dementia Research Institute at the University of Cambridge. She is a specialist in neurodegenerative diseases.

<span class="mw-page-title-main">Alzheon</span>

Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts. The company is developing medicines for patients with Alzheimer's disease and other neurological and psychiatric disorders.

Ali Maximilian Ertürk is a neuroscientist, inventor, and artist living in Munich, Germany. He is the director of a new Helmholtz Institute on Tissue Engineering and Regenerative Medicine (iTERM) in Munich since July 2019 and professor at the medical faculty. After his undergraduate study at Bilkent University in Ankara, he joined Max-Planck-Institute for Neurobiology for his PhD and Genentech Inc. for postdoctoral research.

<span class="mw-page-title-main">Phenserine</span> Chemical compound

Phenserine is a synthetic drug which has been investigated as a medication to treat Alzheimer's disease (AD), as the drug exhibits neuroprotective and neurotrophic effects.

<span class="mw-page-title-main">Peter Elliott (pharmacologist)</span> British pharmacologist (born 1958)

Peter Elliott is a British pharmacologist and drug developer who has initiated clinical trials across a range of disease areas, and is the co-developer of Velcade, a drug used to treat multiple myeloma.

References

  1. ↑ "Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update". Athira Pharma. 2021-08-16. Retrieved 2021-10-20.
  2. ↑ "ADDF Funding Advances M3 Biotechnology Toward Clinical Trials | Alzheimer's Drug Discovery Foundation". www.alzdiscovery.org. Retrieved 2018-10-15.
  3. ↑ "First Trial of Alzheimer's Drug Underway | Science and Enterprise". sciencebusiness.technewslit.com. 17 October 2017. Retrieved 2018-10-15.
  4. ↑ "Individual Grants | Life Sciences Discovery Fund". www.lsdfa.org. Retrieved 2018-07-31.
  5. ↑ "Entrepreneurship has grown on M3 Biotechnology's CEO". The Seattle Times. 2017-04-30. Retrieved 2018-07-31.
  6. ↑ "Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer". Athira Pharma - Company Press Releases. October 21, 2021. Retrieved July 10, 2022.
  7. 1 2 Soper, Taylor (October 21, 2021). "Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation". GeekWire. Archived from the original on October 21, 2021. Retrieved July 10, 2022.
  8. ↑ "M3 Biotechnology Company Profile: Valuation & Investors | PitchBook". pitchbook.com. Retrieved 2018-10-15.
  9. ↑ Inc, Athira Pharma. "M3 Biotechnology Announces Name Change to Athira Pharma, Inc". www.prnewswire.com (Press release). Retrieved 2019-04-15.{{cite press release}}: |last= has generic name (help)
  10. ↑ "Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma". FierceBiotech. Retrieved 2021-10-20.
  11. ↑ Delgado, Diana Campelo (12 October 2020). "Dosing Starts in Phase 2/3 Trial of Athira's ATH-1017 for Alzheimer's" . Retrieved 2021-08-30.
  12. ↑ "Our Approach". Athira Pharma. Retrieved 2021-10-20.
  13. ↑ "M3 Biotechnology Launches Clinical Trials for Alzheimer's Disease Drug Focused on Restoring Lost Connections in the Brain" . Retrieved 2018-10-15.
  14. ↑ Athira Pharma (2021-08-24). "A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease".{{cite journal}}: Cite journal requires |journal= (help)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.